{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"37.0","value":"12.3"},{"groupId":"OG001","lowerLimit":"13.4","upperLimit":"43.1","value":"23.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.","id":"OG000","title":"Phase II Arm I (Pomalidomide, Dexamethasone)"},{"description":"Patients receive pomalidomide, dexamethasone, and ixazomib as in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Phase II Arm II (Pomalidomide, Dexamethasone, Ixazomib)"}],"paramType":"MEDIAN","populationDescription":"All eligible phase 2 responders","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Duration of Response (DOR), Calculated for All Patients Achieving an Objective Response, Partial Response (PR) or Better (Phase II)","type":"SECONDARY","unitOfMeasure":"Months"}